Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
DiaMedica Therapeutics, Inc. (DMAC) had Normalized Income after Taxes of $-7.70M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-7.70M |
|
-- |
|
-- |
|
$8.01M |
|
$-8.01M |
|
$0.31M |
|
$-7.69M |
|
$-7.69M |
|
$-7.70M |
|
$-7.70M |
|
$-7.70M |
|
|
Normalized Income after Taxes |
$-7.70M |
$-8.01M |
|
$-8.18M |
|
42.96M |
|
42.96M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$31.08M |
|
$0.15M |
|
$0.39M |
|
$31.47M |
|
$4.12M |
|
$0.01M |
|
$0.18M |
|
$4.30M |
|
$27.17M |
|
$27.17M |
|
$27.17M |
|
43.07M |
|
| Cash Flow Statement Financials | |
$-14.75M |
|
$15.58M |
|
$0.25M |
|
$3.02M |
|
$4.11M |
|
$1.08M |
|
$1.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.55 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.34% |
|
-28.34% |
|
-24.46% |
|
-28.33% |
|
$0.63 |
|
$-0.34 |
|
$-0.34 |
|